Monthly Archives: June 2011

Five things you need to know about the state of the industry

Höhere Erträge bei Trockenheit / Improving crop yields under dry conditions

What is the state of the biotechnology industry? To find out where the it stands and what strategies you need to survive, read Ernst & Young’s 25th annual industry report, Beyond borders: global biotechnology report 2011, that was released during a super session at the 2011 BIO International Convention. What were the industry’s profits last year? What kind of companies received funding? How should you engage the regulators? What new competencies do you need to Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Evolution of Biotech Industry is a Constant

2593255321_552f8976f3

Healthcare being delivered by smartphone, homes containing treatment capabilities now only found in hospitals, groundbreaking innovations rising from the confluence of technology and science. Change is constant in the biotech industry and few industry experts know its evolution better than Steven Burrill. Burrill, CEO of Burrill and Company, presented his 25th anniversary annual report on the state of the biotech industry Biotech 2011-Life Sciences: Looking Back to See Ahead at the 2011 BIO International Convention Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Biologics & Biosimilars: What is the Science Telling Us?

5161819684_322d02e59a

Panelists from the varied backgrounds of academia, business and regulation agreed on the highest scientific standards of biosimilar regulation. Each panelist emphasized the need for the most stringent of standards in order to ensure patient safety and efficacy within the emerging biosimilars market. As Brian Liang, Executive Director of the Institute of Health Law Studies at California Western School of Law, summed it up, “the need in biosimilars is to focus on science, not cost. These are Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Biotech Business: Wait Our Model Isn’t Dead

Life sciences company and investment executives debated the current and future viability of the industry model for startup companies, given the tumultuous economic waters it traversed during the so-called Great Recession of 2008-2009. The aptly-named panel (“Wait, Our Model Isn’t Dead! We Just Need to Evolve”) appraised those lean times for biotech in a justifiable effort to explain the dramatic decline of startup generation and flow of available investment funding since the peak of the Read More >

Business of Biotech  |  1 Comment  |  Email This Post
Tags:

Our commitments to help heal, fuel and feed the world

Stephen Sherwin MD

By Stephen Sherwin, Former Chairman of BIO All of us who have chosen careers in biotech began our journey because we passionately believe in the ability of our industry to improve the human condition. For many of us, this means devoting our career to improving the treatment of incurable diseases. For others, this means employing the power of biotech to provide high-quality and healthy food for everyone on this planet. And, for still others it Read More >

Corporate  |  Leave a comment  |  Email This Post
Tags: , , , ,